Larimar Therapeutics announces common stock offering, no amount given

Larimar Therapeutics (LRMR) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants in the proposed offering are to be sold by Larimar. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering. Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp and other pipeline candidates, and for working capital and general corporate purposes, including research and development expenses and pre-commercialization expenses. Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.